RMD:NYSEResMed Inc. Analysis

ResMed (RMD) is trading at $252.93, just above its 20‑day SMA (≈$257) and marginally below the 50‑day SMA (≈$255), indicating a price that is testing short‑term support while still respecting longer‑term averages. The RSI sits at 45.8, suggesting neutral momentum, but the MACD histogram is negative and the signal line is bearish, hinting at short‑term downside pressure. Volatility over the past 30 days is high at 32.4% and beta is modest at 0.67, reflecting a stock that moves sharply but is less correlated with the broader market. The Fear & Greed Index reads “Extreme Greed,” which may be inflating demand in the near term.
Fundamentally, RMD posted 11% revenue growth, a 61% gross margin and a 27.5% profit margin, with EPS accelerating 15.6% YoY in the latest quarter. The forward PE of 20.8 is slightly below the industry average of 25.4, and the DCF‑derived fair value of $217.77 leaves the market price about 17.6% above intrinsic, yet still below the consensus target median of $300, implying upside potential. Dividend sustainability looks strong with a 0.95% yield, a low 22% payout ratio and robust free cash flow. Recent earnings beat and margin expansion provide a catalyst, but technical indicators and decreasing volume suggest caution in the very short run.